AI assistant
Sending…
NovoCure Ltd — Director's Dealing 2021
Mar 9, 2021
31949_dirs_2021-03-09_fcf0bbb4-d0b5-4a08-b415-7fee799ac352.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-03-05
Reporting Person: Shah Pritesh (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-05 | Ordinary Shares | M | 13987 | $7.15 | Acquired | 111973 | Direct |
| 2021-03-05 | Ordinary Shares | S | 4550 | $131.53 | Disposed | 107423 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-05 | Options to Buy Ordinary Shares | $7.15 | M | 13987 | Disposed | 2027-02-21 | Ordinary Shares (13987.0) | Direct |
Footnotes
F1: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah.
F2: Fully vested as of the date hereof.
More from NovoCure Ltd
Proxy Solicitation & Information Statement
2026
May 21
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 24
Regulatory Filings
2026
Apr 9
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 26
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3